Product nameAnti-Alpha-synuclein antibody [4D6]
See all Alpha-synuclein primary antibodies
DescriptionMouse monoclonal [4D6] to Alpha-synuclein
Tested applicationsSuitable for: IHC-FoFr, WB, IHC-P, IHC-Fr, ELISAmore details
Unsuitable for: Flow Cyt or ICC
Species reactivityReacts with: Mouse, Rat, Human
Recombinant full length protein corresponding to Human Alpha-synuclein.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferConstituent: PBS
Concentration information loading...
PurityProtein A purified
Purification notesAmmonium sulfate precipitated and dialyzed tissue culture supernatant.
Our Abpromise guarantee covers the use of ab1903 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-FoFr||1/300. PubMed: 17227870Perfuse with 4% paraformaldehyde with 0.4% picric acid in 0.16 M phosphate buffer and postfix.|
|WB||1/100 - 1/10000. Predicted molecular weight: 16 kDa.|
|IHC-P||1/100 - 1/1000. Antigen retrieval is not essential but may optimise staining.|
|IHC-Fr||1/100 - 1/1000.|
|ELISA||Use at an assay dependent concentration.|
FunctionMay be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
Tissue specificityExpressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
Involvement in diseaseGenetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
Parkinson disease 1
Parkinson disease 4
Dementia Lewy body
Sequence similaritiesBelongs to the synuclein family.
DomainThe 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
modificationsPhosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
Ubiquitinated. The predominant conjugate is the diubiquitinated form.
Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure.
Cellular localizationCytoplasm, cytosol. Membrane. Nucleus. Cell junction, synapse. Secreted. Membrane-bound in dopaminergic neurons.
- Information by UniProt
- Alpha synuclein antibody
- Alpha-synuclein antibody
- Alpha-synuclein, isoform NACP140 antibody
All lanes : Anti-Alpha-synuclein antibody [4D6] (ab1903) at 5 µg/ml
Lane 1 : A549 (Human lung adenocarcinoma epithelial cell line) Whole Cell Lysate
Lane 2 : SK N BE (Human neuroblastoma) Whole Cell Lysate
Lane 3 : SK N SH (Human neuroblastoma) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat polyclonal to Mouse IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Predicted band size: 16 kDa
Observed band size: 16 kDa
Additional bands at: 18 kDa (possible post-translational modification), 80 kDa (possible post-translational modification)
IHC-P using ab1903 showing lewy bodies in a substantia nigra neuron(x400)
This product has been referenced in:
- Gerson JE et al. Tau oligomers mediate a-synuclein toxicity and can be targeted by immunotherapy. Mol Neurodegener 13:13 (2018). Read more (PubMed: 29544548) »
- Li Y et al. The Protective Role of Brain CYP2J in Parkinson's Disease Models. Oxid Med Cell Longev 2018:2917981 (2018). Read more (PubMed: 30046373) »